+

PE20040666A1 - Derivados novedosos de piperidina - Google Patents

Derivados novedosos de piperidina

Info

Publication number
PE20040666A1
PE20040666A1 PE2003000705A PE2003000705A PE20040666A1 PE 20040666 A1 PE20040666 A1 PE 20040666A1 PE 2003000705 A PE2003000705 A PE 2003000705A PE 2003000705 A PE2003000705 A PE 2003000705A PE 20040666 A1 PE20040666 A1 PE 20040666A1
Authority
PE
Peru
Prior art keywords
alkyl
halo
compounds
cyane
fluorophenoxy
Prior art date
Application number
PE2003000705A
Other languages
English (en)
Inventor
Laura Cook Blumberg
Christopher Stanley Poss
Matthew Merrill Hayward
Matthew Frank Brown
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20040666A1 publication Critical patent/PE20040666A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA I, DONDE a ES 1-5; b ES 0-4; c ES 0-1; Q ES ALQUILO C1-C6; W ES ARILO C6-C10 O HETEROARILO C2-C9; Y ES O O NR8; R8 ES H O ALQUILO C1-C6; Z ES O O R9; R9 ES H, ALQUILO C1-C6 O ACETILO; R1 ES H, HALO, CIANO, NITRO, ENTRE OTROS; R2, R3, R4 Y R5 SON CADA UNO H, ALQUILO C1-C6 OPCIONALMENTE SUSTITUIDO CON 1-3 GRUPOS HALO; R6 ES H, HALO, ALQUILO C1-C6, CIANO, ENTRE OTROS; R7 ES H, HALO, ALQUILO C1-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-(4-CLOROFENOXI)-1-(4-FENOXIPIPERIDIN-1-IL)ETANONA; 5-CLORO-2-{2-[4-(4-FLUOROFENOXI)PIPERIDIN-1-IL]-2-OXOETOXI}BENZAMIDA Y ACIDO (2,4-CIS)-(2,5-TRANS)-5-CLORO-2-{2[4-(4-FLUOROFENOXI)-2,5-DIMETILPIPERIDIN-1-IL]-2-OXO-ETOXI}-FENIL)-ACETICO. SE REFIERE TEMBIEN A UNA COMPOSICION FARMACEUTICA RELACIONADA. DICHOS COMPUESTOS SON INHIBIDORES DE MIP-1a (CCL3) UTILES EN EL TRATAMIENTO O PREVENCION DE ENFERMEDADES INMUNITARIAS
PE2003000705A 2002-07-18 2003-07-15 Derivados novedosos de piperidina PE20040666A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39710802P 2002-07-18 2002-07-18

Publications (1)

Publication Number Publication Date
PE20040666A1 true PE20040666A1 (es) 2004-09-25

Family

ID=30770997

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000705A PE20040666A1 (es) 2002-07-18 2003-07-15 Derivados novedosos de piperidina

Country Status (24)

Country Link
US (1) US20040063759A1 (es)
EP (1) EP1534677A1 (es)
JP (1) JP2005537279A (es)
KR (1) KR20050021497A (es)
CN (1) CN1668592A (es)
AP (1) AP2005003200A0 (es)
AR (1) AR040583A1 (es)
AU (1) AU2003242941A1 (es)
BR (1) BR0312946A (es)
CA (1) CA2492651A1 (es)
EC (1) ECSP055547A (es)
HN (1) HN2003000222A (es)
IL (1) IL166010A0 (es)
IS (1) IS7614A (es)
MA (1) MA27326A1 (es)
MX (1) MXPA05000380A (es)
OA (1) OA12885A (es)
PA (1) PA8575901A1 (es)
PE (1) PE20040666A1 (es)
TN (1) TNSN05014A1 (es)
TW (1) TW200402416A (es)
UY (1) UY27897A1 (es)
WO (1) WO2004009550A1 (es)
ZA (1) ZA200500067B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399790B2 (en) 2001-02-28 2008-07-15 Konowalchuk Thomas W Virucidal compositions
US7493363B2 (en) 2001-09-19 2009-02-17 Microsoft Corporation Peer-to-peer group management and method for maintaining peer-to-peer graphs
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
MXPA04012393A (es) 2002-06-12 2005-06-17 Chemocentryx Derivados de piperazina 1-aril-4-substituidos para utilizar como antagonistas ccr1 para tratamiento de inflamacion y desordenes inmunes.
CA2492110A1 (en) * 2002-07-18 2004-01-29 Pfizer Products Inc. Bicyclic piperidine derivatives as antagonists of the ccr1 chemokine receptor
US8261062B2 (en) 2003-03-27 2012-09-04 Microsoft Corporation Non-cryptographic addressing
US7230022B2 (en) 2004-02-19 2007-06-12 Bristol-Myers Squibb Company Substituted fused bicyclic amines as modulators of chemokine receptor activity
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
US7381738B2 (en) 2004-02-19 2008-06-03 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7288563B2 (en) 2004-02-19 2007-10-30 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
CA2558211C (en) 2004-03-03 2013-09-03 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7929689B2 (en) 2004-06-30 2011-04-19 Microsoft Corporation Call signs
US20060167044A1 (en) * 2004-12-20 2006-07-27 Arnaiz Damian O Piperidine derivatives and their use as anti-inflammatory agents
US7620902B2 (en) 2005-04-20 2009-11-17 Microsoft Corporation Collaboration spaces
US7617281B2 (en) 2005-04-25 2009-11-10 Microsoft Corporation System and method for collaboration with serverless presence
US7660851B2 (en) 2005-07-06 2010-02-09 Microsoft Corporation Meetings near me
NZ565062A (en) 2005-07-26 2011-02-25 Glaxo Group Ltd Benzylpiperazine derivates and their use in treating conditions mediated by GPR38 receptors
US7576106B2 (en) 2005-10-11 2009-08-18 Chemocentryx, Inc. Piperidine derivatives and methods of use
US8086842B2 (en) 2006-04-21 2011-12-27 Microsoft Corporation Peer-to-peer contact exchange
US8069208B2 (en) 2006-04-21 2011-11-29 Microsoft Corporation Peer-to-peer buddy request and response
US8586571B2 (en) * 2007-10-18 2013-11-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2010077915A1 (en) * 2008-12-17 2010-07-08 Forest Laboratories Holdings Limited Novel compounds useful as cc chemokine receptor ligands
EP3083596A1 (en) 2013-12-18 2016-10-26 Basf Se Azole compounds carrying an imine-derived substituent

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (es) * 1962-12-19
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
AU1208397A (en) * 1995-12-28 1997-07-28 Takeda Chemical Industries Ltd. Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
AU779954B2 (en) * 1999-05-18 2005-02-24 Teijin Limited Remedies or preventives for diseases in association with chemokines
AR028947A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
KR100890676B1 (ko) * 2001-07-24 2009-03-26 리히데 게데온 베기에스제티 기아르 알티 신규한 카르복시산 아미드 화합물

Also Published As

Publication number Publication date
CN1668592A (zh) 2005-09-14
BR0312946A (pt) 2005-07-12
ZA200500067B (en) 2005-11-02
JP2005537279A (ja) 2005-12-08
EP1534677A1 (en) 2005-06-01
KR20050021497A (ko) 2005-03-07
HN2003000222A (es) 2004-11-23
AR040583A1 (es) 2005-04-13
IS7614A (is) 2004-12-23
TNSN05014A1 (fr) 2007-05-14
UY27897A1 (es) 2004-02-27
AU2003242941A1 (en) 2004-02-09
PA8575901A1 (es) 2004-07-20
MA27326A1 (fr) 2005-05-02
AP2005003200A0 (en) 2005-03-31
OA12885A (en) 2006-09-15
US20040063759A1 (en) 2004-04-01
CA2492651A1 (en) 2004-01-29
TW200402416A (en) 2004-02-16
IL166010A0 (en) 2006-01-15
MXPA05000380A (es) 2005-03-31
WO2004009550A1 (en) 2004-01-29
ECSP055547A (es) 2005-03-10

Similar Documents

Publication Publication Date Title
PE20040666A1 (es) Derivados novedosos de piperidina
PE20020476A1 (es) Derivados de glucopiranosiloxibencilbenceno y composiciones farmaceuticas que comprenden los mismos
NO20083411L (no) Indaneddiksyrederivater og deres anvendelse som farmasoytiske midler, intermediater og fremgangsmater for fremstilling
BR122012009489B8 (pt) processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso
NO20051600L (no) 1,4-disubstituerte piperidinderivater og anvendelse derav som 11-betaHSD1 inhibitorer
PE20080768A1 (es) Compuestos de isoindolina 5-sustituidos
PE20060693A1 (es) Nuevos derivados de trifluorometansulfonanilida oxamida eter
EA199800290A1 (ru) (метилсульфонил) фенил-2-(5н)-фураноны в качестве ингибиторов циклооксигеназы-2
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
DE60130771D1 (de) Substituierte heterocyclische amide
NO965334L (no) Nye 4,6-diarylpyrimidin-derivater og salter derav
DE69813896D1 (de) Alpha-aminoamidderivate die als analgetische mittel nützlich sind
PE20050012A1 (es) Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
AR066972A1 (es) Derivados azapeptidicos
NO20055977L (no) Nye benzimidazolderivater
EA200401053A1 (ru) Оксо-азабициклические соединения
CY1109376T1 (el) Παραγωγα υδαντοϊνης χρησιμα ως αναστολεις μεταλλοπρωτεϊνασης
DK1206484T3 (da) Antipicornavirale forbindelser og sammensætninger, deres farmaceutiske anvendelser og materialer til deres syntese
PE20030718A1 (es) Lactamas como antagonistas de taquiquininas
AR030203A1 (es) Derivados de carbamato de 2-(s)-hidroximutilina, composiciones farmaceuticas que los comprenden, procedimiento para prepararlos y 2(s), 11-dihidroxi protegida-mutilina como compuesto intermediario
EA200500348A1 (ru) N-арилпиперидинзамещенные бифенилкарбоксамиды в качестве ингибиторов секреции аполипопротеина b
PE20040750A1 (es) Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3
ATE476431T1 (de) Piperidin- und azetidinderivate als glyt1- inhibitoren
PE20040668A1 (es) Nuevos derivados de piperidina

Legal Events

Date Code Title Description
FC Refusal
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载